Influence of Genistein on Hepatic Lipid Metabolism in an In Vitro Model of Hepatic Steatosis

• Published in: Molecules (Basel, Switzerland) Vol. 26; no. 4; p. 1156
• Main Authors: Seidemann, Lena, Krüger, Anne, Kegel-Hübner, Victoria, Seehofer, Daniel, Damm, Georg
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 22-02-2021; MDPI
• Subjects: Cells, Cultured; Colorimetry; Cytotoxicity; Dose-Response Relationship, Drug; Drug therapy; Endoplasmic reticulum; Enzymes; Fatty acids; Fatty liver; Fatty Liver - drug therapy; Fatty Liver - metabolism; Gene expression; Genistein; Genistein - pharmacology; Hepatocytes; Homeostasis; Humans; Isoflavones; Lipid metabolism; Lipid Metabolism - drug effects; Lipids; Lipogenesis; Liver; Liver - drug effects; Liver - metabolism; Liver diseases; Medical treatment; Metabolic syndrome; Models, Biological; NAFLD; NASH; Oxidation; PPAR alpha - genetics; PPAR alpha - metabolism; primary human hepatocytes; Proteins; RNA, Messenger - genetics; RNA, Messenger - metabolism; Steatosis; Sterol Regulatory Element Binding Protein 1 - antagonists & inhibitors; Sterol Regulatory Element Binding Protein 1 - genetics; Sterol Regulatory Element Binding Protein 1 - metabolism; Sterol regulatory element-binding protein; Transcription factors; NAFLD; liver; primary human hepatocytes; Genistein; NASH; PPARα; SREBP-1c; steatosis
• ISSN: 1420-3049; 1420-3049
• DOI: 10.3390/molecules26041156

Nonalcoholic fatty liver disease (NAFLD) is among the leading causes of end-stage liver disease. The impaired hepatic lipid metabolism in NAFLD is exhibited by dysregulated PPARα and SREBP-1c signaling pathways, which are central transcription factors associated with lipid degradation and de novo lipogenesis. Despite the growing prevalence of this disease, current pharmacological treatment options are unsatisfactory. Genistein, a soy isoflavone, has beneficial effects on lipid metabolism and may be a candidate for NAFLD treatment. In an in vitro model of hepatic steatosis, primary human hepatocytes (PHHs) were incubated with free fatty acids (FFAs) and different doses of genistein. Lipid accumulation and the cytotoxic effects of FFAs and genistein treatment were evaluated by colorimetric and enzymatic assays. Changes in lipid homeostasis were examined by RT-qPCR and Western blot analyses. PPARα protein expression was induced in steatotic PHHs, accompanied by an increase in CPT1L and ACSL1 mRNA. Genistein treatment increased PPARα protein expression only in control PHHs, while CPTL1 and ACSL1 were unchanged and PPARα mRNA was reduced. In steatotic PHHs, genistein reversed the increase in activated SREBP-1c protein. The model realistically reflected the molecular changes in hepatic steatosis. Genistein suppressed the activation of SREBP-1c in steatotic hepatocytes, but the genistein-mediated effects on PPARα were abolished by high hepatic lipid levels.